Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

RAIN
Rain Enhancement Technologies Holdco, Inc. Class A Common Stock
stock NASDAQ

At Close
May 16, 2025 3:59:30 PM EDT
6.83USD-14.883%(+6.83)60,526
0.00Bid   0.00Ask   0.00Spread
Pre-market
Dec 31, 1969 7:00:00 PM EST
0.00USD0.000%(0.00)0
After-hours
May 15, 2025 4:11:30 PM EDT
6.28USD+6.522%(+6.28)0
OverviewHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
08:00AM EST  Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced thatAvanish Vellanki, co-founder, chairman and chief executive officer of Rain, will provide a corporate overview followed by a moderated Q&A at the virtual SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18th at 1:40 pm ET.   GlobeNewswire Inc
Jan 25, 2022
08:00AM EST  B. Riley Securities virtualpresentation scheduled for January 27th at 3:30 pm ET   GlobeNewswire Inc
Jan 11, 2022
04:17AM EST  Rain Therapeutics 10%+ Owner Mark Lampert Reported Purchase of 557,728 Shares @ Avg Price of $12.00/Share in Form 4 Filing on Monday   Benzinga
Jan 5, 2022
08:06AM EST  Rain Therapeutics And Roche To Collaborate On Clinical Trial Of Milademetan Combination With Anti-PD-L1 Immunotherapy For Various Solid Tumor Indications   Benzinga
08:00AM EST  Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced a clinical supply agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the supply of the anti-Programmed Death Ligand-1 (PD-L1) monoclonal antibody, atezolizumab.   GlobeNewswire Inc
Dec 21, 2021
08:00AM EST  Rain Therapeutics to Present at Upcoming Investor Conferences   GlobeNewswire Inc
Dec 14, 2021
08:13AM EST  Rain Therapeutics Reports Will Be Added To NASDAQ Biotech Index, Effective Monday, Dec. 20, 2021   Benzinga
08:00AM EST  Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced it will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective as of market open on Monday, December 20, 2021.   GlobeNewswire Inc
Nov 22, 2021
10:05AM EST  Rain Therapeutics to Present at Upcoming Investor Conferences   GlobeNewswire Inc
Nov 19, 2021
08:17AM EST  Rain Therapeutics Doses First Patient In Phase 2 Basket Trial Of Milademetan For MDM2-Amplified Advanced Solid Tumors   RTTNews
08:00AM EST  Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced that the first patient has been dosed in the multicenter, single arm, open-label, Phase 2 basket trial evaluating milademetan, an oral mouse double minute 2 (MDM2) inhibitor, for the treatment ofMDM2-amplified advanced solid tumors.   GlobeNewswire Inc
Nov 10, 2021
08:22AM EST  Rain Therapeutics Q3 EPS $(0.70) Up From $(3.05) YoY   Benzinga
08:00AM EST  New Phase 2 clinical trial planned for milademetan in Merkel cell carcinoma (MCC), the MANTRA-3 trial, to start in mid-2022   GlobeNewswire Inc
04:09AM EST  Earnings Scheduled For November 10, 2021   Benzinga
Nov 9, 2021
11:42AM EST  Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3) Of Milademetan   Benzinga
08:00AM EST  The Merkel cell trial will be prioritized over the previously planned Phase 2 trial in patients with intimal sarcoma, and will evaluate milademetan in patients with IO-refractory disease   GlobeNewswire Inc
Nov 3, 2021
08:00AM EDT  Rain Therapeutics to Report Third Quarter 2021 Financial Results   GlobeNewswire Inc
Oct 25, 2021
08:00AM EDT  Rain Therapeutics Inc., (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced that it will host a virtual Research and Development (R&D) day on Tuesday, November 9, 2021 from 11:00 am to 2:00 pm Eastern Time.   GlobeNewswire Inc
Oct 12, 2021
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Oct 7, 2021
10:01AM EDT  Rain Therapeutics Presents Data On Milademetan (RAIN-32) At 2021 AACR-NCI-EORTC Virtual International Conference   Benzinga
10:00AM EDT  Rain Therapeutics Inc., (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced data on its oral mouse double minute 2 (MDM2) inhibitor, milademetan, presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics held virtually October 7-10, 2021.   GlobeNewswire Inc
Oct 4, 2021
08:08AM EDT  Rain Therapeutics To Present On Milademetan At 2021 AACR-NCI-EORTC Virtual International Conference On Molecular Targets And Cancer Therapeutics   Benzinga
08:00AM EDT  Rain Therapeutics to Present on Milademetan at the 2021   GlobeNewswire Inc
Sep 22, 2021
08:00AM EDT  Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference being held virtually September 27-30, 2021.   GlobeNewswire Inc
Sep 21, 2021
08:20AM EDT  The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data   Benzinga
Sep 18, 2021
12:14PM EDT  The Past Week's Notable Insider Buys: Continental Resources, Oscar Health And More   Benzinga
Sep 9, 2021
08:00AM EDT  Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.   GlobeNewswire Inc
Sep 8, 2021
08:00AM EDT  Rain Therapeutics Presents Non-Clinical Data on Milademetan   GlobeNewswire Inc
Sep 1, 2021
08:02AM EDT  Rain Therapeutics To Present At IASLC 2021 World Conference On Lung Cancer And Participate In Panel Discussion At Citi 16th Annual Biopharma Virtual Conference   Benzinga
08:00AM EDT  Rain Therapeutics to Present at IASLC 2021 World Conference on   GlobeNewswire Inc
Aug 10, 2021
08:06AM EDT  Rain Therapeutics Q2 EPS $(0.39) Beats $(0.60) Estimate   Benzinga
08:00AM EDT  First patient dosed in Phase 3 registrational trial (MANTRA) evaluating milademetan (RAIN-32) in patients with dedifferentiated (DD) liposarcoma (LPS)   GlobeNewswire Inc
04:05AM EDT  Earnings Scheduled For August 10, 2021   Benzinga
Aug 3, 2021
08:00AM EDT  Rain Therapeutics to Report Second Quarter 2021 Financial Results   GlobeNewswire Inc
Jul 28, 2021
03:12PM EDT  Rain Therapeutics ClinicalTrials.gov Study Record Detail For Co.'s 'Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma (MANTRA) (MANTRA)'; Shows Study Is Recruiting   Benzinga
03:12PM EDT  Rain Therapeutics ClinicalTrials.gov Study Record Detail For Co.'s 'Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma (MANTRA) (MANTRA)'   Benzinga
Jul 20, 2021
08:06AM EDT  Rain Therapeutics Initiates Phase 3 MANTRA Clinical Trial Of Milademetan For De-Differentiated Liposarcoma   Benzinga
08:00AM EDT  The randomized, multi-center, open-label Phase 3 trial will evaluate the efficacy and safety of milademetan in patients with de-differentiated (DD) liposarcoma (LPS)   GlobeNewswire Inc
Jul 11, 2021
05:10PM EDT  The Past Week's Notable Insider Buys Include Krispy Kreme, Biotechs, SPACs And More   Benzinga
Jul 7, 2021
05:20AM EDT  Rain Therapeutics Director Mark Lampert Reported Purchase of 587,002 Shares @ Avg Price of $15.47/Share in Form 4 Filing on Tuesday   Benzinga
Jun 3, 2021
08:01AM EDT  Rain Therapeutics Reports Collaboration With Tempus For Genomic Analysis in Planned MDM2-Amplified Phase 2 Basket Trial of RAIN-32   Benzinga
08:00AM EDT  Rain Therapeutics Announces Collaboration with Tempus for Genomic   GlobeNewswire Inc
Jun 2, 2021
08:01AM EDT  Rain Therapeutics Announces Patient Referral Partnership For Planned MDM2-Amplified Phase 2 Basket Trial Of RAIN-32   Benzinga
08:00AM EDT  Rain Therapeutics Announces Patient Referral Partnership for the   GlobeNewswire Inc
May 27, 2021
08:00AM EDT  Rain Therapeutics to Present at the Goldman Sachs 42nd Annual   GlobeNewswire Inc
May 25, 2021
08:16AM EDT  Rain Therapeutics CEO Says 'We Also Continue To Expect The Start Of A Third Clinical Study, In Intimal Sarcoma By Early 2022'   Benzinga
08:15AM EDT  Rain Therapeutics Q1 EPS $(1.93) Down From $(0.82) YoY   Benzinga
08:00AM EDT  Completed initial public offering ("IPO") with net proceeds of $121.9 million   GlobeNewswire Inc
May 20, 2021
08:02AM EDT  Rain Therapeutics Appoints Robert Doebele, M.D., Ph.D. as President   Benzinga
May 18, 2021
10:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021   Benzinga
08:19AM EDT  Guggenheim Initiates Coverage On Rain Therapeutics with Buy Rating, Announces Price Target of $26   Benzinga
07:02AM EDT  Piper Sandler Initiates Coverage On Rain Therapeutics with Overweight Rating, Announces Price Target of $25   Benzinga
07:01AM EDT  Goldman Sachs Initiates Coverage On Rain Therapeutics with Buy Rating, Announces Price Target of $56   Benzinga
06:27AM EDT  Citigroup Initiates Coverage On Rain Therapeutics with Buy Rating, Announces Price Target of $28   Benzinga
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 2, 2021
08:05AM EDT  Last Week's Notable Insider Buys: Beacon Roofing, Chipotle, IPOs, Latham And More   Benzinga
Apr 27, 2021
07:41AM EDT  The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout   Benzinga
Apr 23, 2021
11:38AM EDT  Rain Therapeutics Shares Open For Trade At $22.10; IPO Priced At $17/Share   Benzinga
11:16AM EDT  Rain Therapeutics Indicates $23.80 On 167K Shares   Benzinga
10:31AM EDT  Rain Therapeutics Indicates $27 On 139K Shares   Benzinga
10:21AM EDT  Rain Therapeutics Indicates $23.80   Benzinga
10:16AM EDT  Rain Therapeutics Indicates $33.15 On 65K Shares   Benzinga
09:09AM EDT  Rain Therapeutics Shares Will Open For Quote At 9:50 a.m. EDT, Expected To Open For Trade After 10 a.m. EDT; IPO Priced At $17/Share   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC